Imaging brain amyloid in Alzheimer's disease with Pittsburgh Compound‐B

By William E. Klunk, H. Engler, A. Nordberg, Yanming Wang, G. Blomqvist, D. Holt, M. Bergström, I. Savitcheva, Guo-feng Huang, S. Estrada and 11 more. Annals of Neurology, 2004

4,543 citations recorded by the source corpus.

Subfields: Neurology, Physiology, Psychiatry and Mental health

View Paper: https://www.semanticscholar.org/paper/54f79667dbe41e9e03f6ee2b12bcc43754b91672

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Neurology

In Physiology

In Psychiatry and Mental health

Citations in the corpus

Altered resting state networks in mild cognitive impairment and mild Alzheimer's disease: An fMRI study (2005, background): “In vivo images of amyloid suggest marked depositions in these areas in AD [Klunk et al., 2004].”
Inverse relation between in vivo amyloid imaging load and cerebrospinal fluid Aβ42 in humans (2006, methodology): “Results All subjects underwent PET imaging with PIB for calculation of in vivo amyloid plaque binding.(8) Visual inspection of the radiolabeled tracer on PET images showed early and rapid uptake of PIB into all brain regions of all subjects, followed by prolonged retention in several cortical and su”
Molecular, Structural, and Functional Characterization of Alzheimer's Disease: Evidence for a Relationship between Default Activity, Amyloid, and Memory (2005, methodology): “Longitudinal atrophy sample Variation in individual uptake of PIB, which may provide an important marker for disease pathology and progression (Klunk et al., 2004), is not analyzed here but will appear in future reports.”
Islet amyloid polypeptide, islet amyloid, and diabetes mellitus. (2011, methodology): “It has already been successfully used for the demonstration of cerebral amyloid in Alzheimer’s disease (189).”
Human apoE isoforms differentially regulate brain amyloid-β peptide clearance (2011, neutral): “Interaction of nascent ApoE2, ApoE3, and ApoE4 isoforms expressed in mammalian cells with amyloid peptide beta (1-40).”
Frequent Amyloid Deposition Without Significant Cognitive Impairment Among the Elderly (2008, neutral): “imaging has made it possible to identify amyloid deposition in vivo.(7) Recent stud-”
NIA-AA Research Framework: Toward a biological definition of Alzheimer’s disease (2018, neutral): “Biomarkers of Ab plaques (labeled “A”) are cortical amyloid PET ligand binding [76,77] or low CSF Ab42 [78–80].”
The Cortical Signature of Alzheimer's Disease: Regionally Specific Cortical Thinning Relates to Symptom Severity in Very Mild to Mild AD Dementia and is Detectable in Asymptomatic Amyloid-Positive Individuals (2008, methodology): “PIB-PET imaging provides an in vivo measure of human brain amyloid in plaques associated with AD (Klunk et al. 2004; Buckner et al. 2005; Mintun et al. 2006).”
Clinical Neurology and Epidemiology of the Major Neurodegenerative Diseases. (2018, background): “PET studies that use tracers that specifically bind amyloid (C11PiB [Klunk et al. 2004; Ikonomovic et al. 2008], F18-florbetapir [Wong et al. 2010; Clark et al. 2011, 2012], F18-flutemetamol [Vandenberghe et al. 2010; Wolk et al. 2011], and F18-florbetaben [Rowe et al. 2008]) can noninvasively…”
Tau PET imaging in aging and early Alzheimer’s disease (2015, background): “A breakthrough reported in 2004 enabled researchers using positron emission tomography (PET) with (11)C Pittsburgh compound B (PiB) to detect Ab deposits in living humans, and Ab PET is now widely used in clinical trials of antiAb therapies to identify individuals with AD pathology.(3) The detection”
Biomarkers for Alzheimer's disease: academic, industry and regulatory perspectives (2010, neutral): “Several studies have shown that selective binding of a 11 C-labelled thioflavin analogue known as Pittsburgh compound B ( 11 C-PIB”
Longitudinal Assessment of Aβ and Cognition in Aging and Alzheimer Disease (2011, background): “Cross-sectional [(11)C]Pittsburgh compound B (PiB) PET studies have shown a robust difference between the retention patterns in DAT patients and healthy controls (HCs).(10,11) In agreement with postmortem data,(2) approximately 20 to 30% of elderly HC subjects show some degree of increased cortical ”
Defining imaging biomarker cut points for brain aging and Alzheimer's disease (2017, positive): “Imaging methods Amyloid PET imaging was performed with Pittsburgh Compound B [38] and tau PET with AV1451 [29].”